Compare L3Harris Technologies Inc (LHX) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

L3Harris Technologies IncTrade

Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

L3Harris Technologies Inc vs Neurocrine Biosciences Inc — how do they compare? L3Harris Technologies Inc trades at $277.71 (market cap $52.27B), while Neurocrine Biosciences Inc trades at $179 (market cap $17.40B). The key difference: L3Harris Technologies Inc is far larger — about 3× Neurocrine Biosciences Inc's market cap, and L3Harris Technologies Inc pays a 1.78% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

	LHX	NBIX
Market Cap	$52.27B	$17.40B
Sector	Industrials	Health
52-Week High	$378.48	$180.55
52-Week Low	$263.09	$123.10
Enterprise Value	$63.03B	$16.49B
Dividend Yield	1.78%	—

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

LHX

OpenAI and Anthropic boost lobbying to $3.17M in Q2 ahead of IPOs and midtermsCNBC · 10 hours agoNeutral View details →

NBIX

Neurocrine Biosciences appoints Samir Siddhanti as Chief Business Officer to lead growth strategy.PRNewsWire · 6 hours agoBullish View details →

About L3Harris Technologies Inc

L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.